{
Sarepta Therapeutics, Inc.

Companies

}
001122334455554433221100
001122334455554433221100
Symbol SRPT
Name Sarepta Therapeutics, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State MA
City Cambridge
Zipcode 2142
Website http://www.sarepta.com
Track all markets on TradingView

analysts divided on sarepta therapeutics after patient death linked to elevidys

Sarepta Therapeutics' shares saw volatility following a patient's death linked to its gene therapy, Elevidys, yet UBS analyst Eliana Merle maintained a Buy rating with a target of USD 188, viewing the market's reaction as an overreaction. Despite the incident, demand for Elevidys remains strong, and revenue growth is robust at 53% year-over-year. Analysts' responses vary, with some expressing caution while others uphold positive outlooks for the company's future performance.
Investing.com France
United States Dollar JPMorgan U.S. Research Enhanced Large Cap ETF Leerink Partners LLC Arrowhead Pharmaceuticals, Inc. REGENXBIO Inc. Cantor Fitzgerald Equity Opp A H.C. Wainwright & Co. LLC Sarepta Therapeutics, Inc. USA Eliana Merle Show more
Finance & Economy, Market Report
16:08 19.03.2025

analysts divided on sarepta therapeutics after patient death linked to elevidys

UBS has maintained a Buy rating for Sarepta Therapeutics with a price target of $188, despite a recent patient death linked to its gene therapy Elevidys, which has caused the stock to drop over 26%. Analyst Eliana Merle views the market reaction as exaggerated and emphasizes the ongoing demand for Elevidys, the only approved treatment for Duchenne muscular dystrophy. While some analysts express caution regarding safety and sales forecasts, others remain optimistic about the drug's potential and future revenue growth.
Investing.com Deutsch
United States Dollar JPMorgan U.S. Research Enhanced Large Cap ETF Leerink Partners LLC Arrowhead Pharmaceuticals, Inc. REGENXBIO Inc. Cantor Fitzgerald Equity Opp A H.C. Wainwright & Co. LLC Sarepta Therapeutics, Inc. USA Eliana Merle Show more
Finance & Economy, Market Report
16:08 19.03.2025

ubs maintains buy rating and price target for sarepta therapeutics

UBS analyst Eliana Merle has reaffirmed a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) with a price target of $188.00. The positive outlook reflects confidence in the company's potential and market position.
StreetInsider.com
Sarepta Therapeutics, Inc. USA Eliana Merle
Finance & Economy, Market Report
15:19 19.03.2025

Barclays calls Sarepta stock reaction overdone after patient death report

Barclays has maintained an Overweight rating and a $209 price target on Sarepta following a patient death linked to Elevidys due to acute liver failure. The firm noted that while the incident was unexpected, liver toxicity was already known, and the stock's reaction appears exaggerated. Initial feedback indicates minimal impact on Elevidys patient usage.
TipRanks Financial
United States Dollar Sarepta Therapeutics, Inc. USA
Finance & Economy, Market Report
22:10 18.03.2025

ubs identifies top 25 us stocks with strong potential for 2025

UBS Global Research has identified 25 US stocks with strong potential for 2025, focusing on technology, healthcare, and industrial sectors. Notable picks include 3M Company, Amazon, CyberArk Software, and Texas Instruments, with expectations of growth driven by strategic initiatives and market demand. Other recommendations include Alaska Air, Mastercard, and Oracle, highlighting an attractive risk/reward ratio for investors.
Investing.com Deutsch
Cognex Corp Elevance Health, Inc. First Citizens BancShares, Inc. Texas Instruments Inc CyberArk Software Ltd. Energy Transfer LP Amazon.com, Inc. Amphenol Corp Sarepta Therapeutics, Inc. KEURIG DR PEPPER Oracle Corp CenterPoint Energy, Inc. AMERICAN TOWER REIT ConocoPhillips 3M Company Alaska Air Group, Inc. Ulta Beauty, Inc. Mastercard Inc Comfort Systems USA, Inc. Legend Biotech Corp Reinsurance Group of America, Incorporated First Solar, Inc. USA CHE Show more
Finance & Economy, Market Report
22:16 19.12.2024

ubs selects top 25 us stocks for growth in 2025

UBS Global Research has identified its top 25 U.S. stock picks for 2025, focusing on companies poised for growth across technology, healthcare, and industrial sectors. Key selections include Amazon, CyberArk Software, and Texas Instruments, with expectations of strong performance driven by strategic initiatives and market recovery. The firm highlights that factors like acquisitions and regulatory clarity will be crucial for these stocks' success.
Investing.com
Cognex Corp First Citizens BancShares, Inc. Texas Instruments Inc CyberArk Software Ltd. Energy Transfer LP Amazon.com, Inc. Amphenol Corp Sarepta Therapeutics, Inc. KEURIG DR PEPPER Oracle Corp CenterPoint Energy, Inc. AMERICAN TOWER REIT ConocoPhillips 3M Company Alaska Air Group, Inc. Ulta Beauty, Inc. Mastercard Inc Comfort Systems USA, Inc. Legend Biotech Corp Reinsurance Group of America, Incorporated First Solar, Inc. USA Show more
Finance & Economy, Market Report
18:35 19.12.2024

ubs selects top 25 us stocks for growth in 2025

UBS Global Research has identified its top 25 U.S. stock picks for 2025, focusing on companies poised for growth across technology, healthcare, and industrial sectors. Key selections include Amazon, CyberArk Software, and Texas Instruments, with an emphasis on strategic acquisitions and innovation driving performance. The firm believes that current market pessimism presents favorable risk-reward scenarios for these stocks.
Investing.com
Sarepta Therapeutics, Inc. Cognex Corp Comfort Systems USA, Inc. Oracle Corp 3M Company Amazon.com, Inc. First Solar, Inc. Alaska Air Group, Inc. CenterPoint Energy, Inc. AMERICAN TOWER REIT KEURIG DR PEPPER ConocoPhillips Amphenol Corp Mastercard Inc Energy Transfer LP Texas Instruments Inc Ulta Beauty, Inc. First Citizens BancShares, Inc. Legend Biotech Corp CyberArk Software Ltd. Reinsurance Group of America, Incorporated USA Show more
Finance & Economy, Market Report
18:35 19.12.2024

promising gene therapy stocks to watch in the evolving biotech landscape

The biotech sector is witnessing renewed interest in gene therapies, particularly following recent FDA approvals. Companies like Sarepta Therapeutics, CRISPR Therapeutics, and Voyager Therapeutics are positioned for growth in 2025, with Sarepta's Elevidys leading the way as the first gene therapy for Duchenne muscular dystrophy. The company is also expanding its pipeline with new treatments for other neuromuscular disorders.
Yahoo Finance
Voyager Therapeutics, Inc. CRISPR Therapeutics AG Sarepta Therapeutics, Inc. USA Show more
Healthcare, Market Report
14:59 17.12.2024

merck acquires cancer startup elevidys sales rise and other industry updates

Merck & Co. has acquired Modifi Biosciences for $30 million, with potential additional payments of up to $1.3 billion based on milestones. Meanwhile, Roche reported that sales of Sarepta's gene therapy Elevidys reached approximately $156 million outside the U.S. in the first nine months of the year. Sangamo Therapeutics is on track to file for accelerated approval of its Fabry disease treatment, while MacroGenics sold rights to its breast cancer drug Margenza for $40 million, with additional milestone payments possible.
BioPharma Dive
United States Dollar Swiss Franc Hoffmann-La Roche AG Merck & Co., Inc. UCB SA Sarepta Therapeutics, Inc. Sangamo Therapeutics, Inc. Ned Pagliarulo Delilah Alvarado Jonathan Gardner Alessandro Maselli Show more
Healthcare, Market Report
17:45 23.10.2024

biotech hedge funds show mixed results as janus henderson leads the pack

The Janus Henderson Biotech Innovation Fund leads biopharma hedge funds with a 39.35% year-to-date gain, despite a less than 1% rise in September. Other funds like Casdin Capital and Averill Partners also performed well, while EcoR1 Capital faced significant losses, down 11.4% for the year.
Institutional Investor
Revolution Medicines, Inc. Amicus Therapeutics, Inc. Sarepta Therapeutics, Inc. BioLife Solutions, Inc. AbbVie Inc. Andy Acker Dan Lyons Joe Biden Show more
Finance & Economy, Market Report
17:35 23.10.2024
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.